BCAX
Bicara Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$17.47
+4.11%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$16.92
From 52W high−42.53%
Volume864787.00
Market cap$1.16B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$16.92
From 52W high
−42.53%
Volume
864787.00
Market cap
$1.16B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.6x
P/E (TTM)
—
RSI (14)
33.9
MomentumView details →
1D Return
+4.11%
YTD Return
+2.08%
SummaryUpdated Jun 1, 2026
Bicara Therapeutics Inc. (NASDAQ:BCAX) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Boston, Massachusetts. The company operates as a subsidiary of Biocon Limited, a major Indian biopharmaceutical company. Bicara focuses on developing innovative bifunctional antibody therapies specifically designed to treat solid tumors, representing a novel approach in cancer treatment that combines two therapeutic mechanisms into a single drug molecule.
Similar companies
Latest newsMore news →
Bicara Therapeutics initiated the FORTIFI-FLEX trial, a pivotal Phase III study, and outlined an interim analysis timeline for mid-2027.69d agoBicara Therapeutics announced leadership changes during its Q2 2026 earnings call.69d agoJeremy Bender was appointed as a Class I Director of the Board of Directors and a member of the Audit Committee and Launch Readiness Committee of Bicara Therapeutics Inc., effective July 28, 2026.84d ago